Bristol-Myers Squibb has served as a strategic partner for the Cancer Research Institute by providing unparalleled support to advance scientific research and educate patients about immunotherapy.
Their collaboration has supported the first online patient portal focused on immunotherapy (TheAnswerToCancer.org), multi-year title sponsorship of the Answer to Cancer cycling events, Cancer Immunotherapy and You webinar series, and Immunotherapy Patient Summit series, including the Inaugural Patient Summit. Bristol-Myers Squibb has also supported the CRI Irvington Postdoctoral Fellowship Program, and the CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference.
In 2014, Bristol-Myers Squibb’s leadership in the field of cancer immunotherapy was recognized with the Cancer Research Institute Oliver R. Grace Award, presented to Murdo Gordon, executive vice president and chief commercial officer, at the Cancer Research Institute Annual Awards Dinner.
*Immunotherapy results may vary from patient to patient.
Cancer Research Institute | National Headquarters
29 Broadway, Floor 4 | New York, NY 10006-3111
(800) 992-2623(212) 832-9376Staff Directory
July is Sarcoma Awareness Month. As a rare and difficult-to-treat form of cancer, effective drug treatments are urgently needed and immunotherapy for sarcoma shows promise.
Dr. Joan Levy, director of research at the Chordoma Foundation, discusses the current state of chordoma research and the recently launched partnership with CRI.